Thymidylate synthase inhibitors for non-small cell lung cancer
- 16 August 2011
- journal article
- review article
- Published by Informa UK Limited in Expert Opinion on Investigational Drugs
- Vol. 20 (10), 1343-1356
- https://doi.org/10.1517/13543784.2011.617742
Abstract
Introduction: The folate-dependent enzyme thymidylate synthase (TS) plays a pivotal role in DNA replication/repair and cancer cell proliferation, and represents a valid target for the treatment of several tumor types, including NSCLC. NSCLC is the leading cause of cancer-related mortality, and several TS inhibitors have gone into preclinical and clinical testing, with pemetrexed emerging for its approval and widespread use as first-/second-line and maintenance therapy for this disease. Areas covered: This review summarizes the therapeutic options in NSCLC, as well as the background and rationale for targeting TS. The authors also review recent pharmacogenetic studies and data from clinical trials evaluating novel TS inhibitors, hoping that the reader will gain a comprehensive overview of the field of TS inhibition, specifically relating to drugs used or being developed for lung cancer patients. Expert opinion: TS is a validated target in NSCLC. However, benefits from conventional chemotherapy in NSCLC have plateaued, and more cost-effective results should be obtained with individualized treatment. Accordingly, the clinical success for TS inhibitors may depend on our ability to correctly administer these agents following biomarker-driven patient selection, including TS genotype and expression, and using the right combination therapy.Keywords
This publication has 89 references indexed in Scilit:
- Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancerBritish Journal of Cancer, 2011
- Interaction between Thymidylate Synthase and Its Cognate mRNA in Zebrafish EmbryosPLOS ONE, 2010
- Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients With Advanced Non–Small-Cell Lung Cancer: NCCTG and SWOG Study N0426Journal of Clinical Oncology, 2010
- American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2009
- Hypermethylation of the human proton-coupled folate transporter (SLC46A1) minimal trancriptional regulatory region in an antifolate-resistant HeLa cell lineMolecular Cancer Therapeutics, 2009
- How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion QuestionJNCI Journal of the National Cancer Institute, 2009
- Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cellsBritish Journal of Cancer, 2008
- The Proton-Coupled Folate Transporter: Impact on Pemetrexed Transport and on Antifolates Activities Compared with the Reduced Folate CarrierMolecular Pharmacology, 2008
- The inverse relationship between reduced folate carrier function and Pemetrexed activity in a human colon cancer cell lineMolecular Cancer Therapeutics, 2006
- Systemic Therapy for Colorectal CancerNew England Journal of Medicine, 2005